AB Dynamics (ABDP)

-

At the beginning of the year I bought AIM super stock, AB Dynamics and after 5 months it has earned a return of over 50%. This is extremely impressive compared to a return of around 12% for the FTSE AIM 100 and a rise of only 7% for the FTSE 100 for the same period. 
The company’s high growth performance isn’t just in isolation either, with the stock producing over a 357% return since the start of 2017, suggesting that this isn’t just a lucky year or an overhyped valuation by the market. So the question is, can the stock continue to grow? 

WHAT THEY DO

AB Dynamics supply integrated test systems for the automotive industry, with a client list that includes major brands such as BMW, Audi, and Chrysler. The stock is currently listed on the FTSE AIM market, with a market cap of £471 million. 

The testing industry may be an unglamorous part of the automotive industry versus investing in brands such as BMW and Rolls Royce, but it is an important part of the value chain for such brands. With strict legislation in place for car safety requirements, testing is a crucial step in the production process and this is where AB Dynamics come in.
The company has managed to benefit from the fact that it is cheaper to hire their abilities to test electric and self-driving cars than it is to produce internal operations. As such, the company is operating in a space where large players don’t want to enter and would rather hire companies with relevant expertise, such as AB Dynamics. 
The company’s underlying fundamentals continue to look strong with a high operating margin of 21% and a return on capital employed at 20% in 2018. This shows that the company is highly effective in its use of capital, and the profit that it produces from sales is above average fuelling growth. This arguably indicates that strong management is in place to lead the business for future growth, along with an effective business model that is currently dominating its niche market. 

TRENDS FOR GROWTH

AB Dynamics due to its positioning is also set to benefit from trends in both driverless and electric vehicles. For example, electric cars are increasingly in demand due to regulatory pressures from the UK government, with the sales of diesel cars in the UK to be banned in 2040. This has lead to an increase in demand for the testing that AB Dynamics supplies. 

Due to recent success, the company has targeted expansion into new markets, with the firm opening a new office in Germany in 2018 to target continental Europe. The company is therefore well-positioned to tap into growing demand in the EU, with Germany the first EU country to legalise automotive driving vehicles. 

OUTLOOK

I think that with the company’s past performance, strong business fundamentals and its strategy to tap into increasing market demand all provide strong indicators for future growth potential for the stock. As a result, I’m going to hold AB Dynamics for the long term to achieve further returns. 


Comments

Post a Comment

Popular posts from this blog

Smith and Nephew (SN)

-
Image
In today’s blog I look at the investment case for Smith and Nephew, a FTSE 100 pharmaceutical giant with a market cap of £14,730 million. Since 2015 the stock has returned over 90% and continues to look attractive going forward. It may not provide the super growth that AIM stocks could potential deliver, but it does provide diversification for your portfolio to balance out risk of investing in small- and mid-cap companies. DEMAND The company has three sectors that it specialises in which are orthopaedics, sports medicine and advanced wound treatment. For example, this includes equipment used in operations for knee replacements and rotator cuff repair. The demand for these business sectors should continue to grow regardless of UK economic conditions, as healthcare is of increasing importance. This is supported by the global trend which can be seen in developing countries such as the US, Smith and Nephew’s highest market by revenue, are moving towards an aging popul
Read more

Bioventix (BVXP)

-
Image
A stock that I have been following for a while now is growth AIM small-cap stock Bioventix, who specialise in sheep antibodies and currently has a market cap of £191 million. The shares currently trade at over £38, which appears expensive at first glance. However, the company has performed extremely well over the last 3 and a half years since 2016, producing a return of 197% for investors. To better understand the stock’s investment potential, investors need to look deeper into the company, researching areas such as its current business model and current financial situation. This will provide a clearer understanding as to whether the stock will provide future returns.  BIOTECHNOLOGY The firm operates in the biotechnology space, specialising in antibodies produced from sheep for use in diagnostic applications, for example, in the testing of drugs of abuse. Some of its top clients include Siemens and Philips, which supply testing machines to hospitals.  These compan
Read more

GB Group (GBG)

-
Image
If you like the look of FTSE 100 data giant Experian then it may be worth looking in a similar sector at the AIM growth company, GB Group. Due to less coverage on the index, there is potential for the stock to achieve relatively higher levels of growth and hence deliver greater returns over the medium to longer-term for investors. WHAT THEY DO GB Group is an identity management company, with a market cap of £1.13 billion and is listed on the software and services sector of the FTSE AIM All-Share index. The company centers on the analysis of data in a variety of services such as user identification, customer on-boarding, and employee screening. GB Group has performed well for investors in the past, achieving a 120% return for investors since 2016. In this blog, I explore why I think the business is positioned to continue to provide superior returns in the long run. BIG DATA I recently spoke about the growing importance of big data in today’s society, with the
Read more